Pulmonary Arterial Hypertension

May 23rd 2024

Preliminary data suggest people with Group 1 pulmonary hypertension had improved outcomes if they had ever received hormone replacement therapy.

May 9th 2024

Research shows health-related quality of life is impacted in major ways by pulmonary arterial hypertension, but a solution to the problem—and the disease itself—has proven elusive.

March 30th 2024

This week, the FDA approved two therapies for pulmonary arterial hypertension: Merck’s first in class therapy Winrevair and J&J’s oral combination tablet Opsynvi. The agency also approved Vafseo, a new treatment for anemia in kidney disease. The FDA granted full approval to the cancer drug Elahere and extended the indication of Vemlidy to children. Regulators also issued a CRL for odronextamab for lymphoma indications

March 26th 2024

Sotatercept — now with the brand name Winrevair — will be available through specialty pharmacies by the end of April. The price of Winrevair is $14,000 per vial.